- Home
- AFMD vs ACHL Comparison
AFMD vs ACHL Comparison
Compare AFMD & ACHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFMD
- ACHL
- Stock Information
- Founded
- AFMD 2000
- ACHL 2016
- Country
- AFMD Germany
- ACHL United Kingdom
- Employees
- AFMD N/A
- ACHL N/A
- Industry
- AFMD Biotechnology: Pharmaceutical Preparations
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AFMD Health Care
- ACHL Health Care
- Exchange
- AFMD Nasdaq
- ACHL Nasdaq
- Market Cap
- AFMD 45.6M
- ACHL 43.6M
- IPO Year
- AFMD 2014
- ACHL 2021
- Fundamental
- Price
- AFMD $1.27
- ACHL $0.95
- Analyst Decision
- AFMD Strong Buy
- ACHL Buy
- Analyst Count
- AFMD 5
- ACHL 2
- Target Price
- AFMD $13.50
- ACHL $4.00
- AVG Volume (30 Days)
- AFMD 498.2K
- ACHL 113.5K
- Earning Date
- AFMD 11-14-2024
- ACHL 11-14-2024
- Dividend Yield
- AFMD N/A
- ACHL N/A
- EPS Growth
- AFMD N/A
- ACHL N/A
- EPS
- AFMD N/A
- ACHL N/A
- Revenue
- AFMD $6,287,085.00
- ACHL N/A
- Revenue This Year
- AFMD N/A
- ACHL N/A
- Revenue Next Year
- AFMD $28.44
- ACHL N/A
- P/E Ratio
- AFMD N/A
- ACHL N/A
- Revenue Growth
- AFMD N/A
- ACHL N/A
- 52 Week Low
- AFMD $1.40
- ACHL $0.63
- 52 Week High
- AFMD $8.95
- ACHL $1.76
- Technical
- Relative Strength Index (RSI)
- AFMD 16.00
- ACHL 29.24
- Support Level
- AFMD $1.40
- ACHL $0.97
- Resistance Level
- AFMD $2.21
- ACHL $1.01
- Average True Range (ATR)
- AFMD 0.24
- ACHL 0.03
- MACD
- AFMD -0.08
- ACHL -0.01
- Stochastic Oscillator
- AFMD 3.33
- ACHL 0.87
About AFMD Affimed N.V.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.